| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Waldman, E Hochhauser, M Fishbein, D Aravot, A Shainberg, Y Sarn. An ultra-low dose of tetrahydrocannabinol provides cardioprotection. Biochemical pharmacology. vol 85. issue 11. 2013-07-16. PMID:23537701. |
tetrahydrocannabinol (thc), the major psychoactive component of marijuana, is a cannabinoid agonist that exerts its effects by activating at least two specific receptors (cb1 and cb2) that belong to the seven transmembrane g-protein coupled receptor (gpcr) family. |
2013-07-16 |
2023-08-12 |
mouse |
| David A Gorelick, Robert S Goodwin, Eugene Schwilke, David M Schwope, William D Darwin, Deanna L Kelly, Robert P McMahon, Fang Liu, Catherine Ortemann-Renon, Denis Bonnet, Marilyn A Huesti. Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. Journal of analytical toxicology. vol 37. issue 1. 2013-07-11. PMID:23074216. |
tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. |
2013-07-11 |
2023-08-12 |
Not clear |
| Paola Massi, Marta Solinas, Valentina Cinquina, Daniela Parolar. Cannabidiol as potential anticancer drug. British journal of clinical pharmacology. vol 75. issue 2. 2013-07-01. PMID:22506672. |
however, the clinical use of Δ(9)-thc and additional cannabinoid agonists is often limited by their unwanted psychoactive side effects, and for this reason interest in non-psychoactive cannabinoid compounds with structural affinity for Δ(9)-thc, such as cannabidiol (cbd), has substantially increased in recent years. |
2013-07-01 |
2023-08-12 |
Not clear |
| Sage J B Dunham, Paul D Hooker, Robyn M Hyd. Identification, extraction and quantification of the synthetic cannabinoid JWH-018 from commercially available herbal marijuana alternatives. Forensic science international. vol 223. issue 1-3. 2013-06-20. PMID:23092847. |
identification, extraction and quantification of the synthetic cannabinoid jwh-018 from commercially available herbal marijuana alternatives. |
2013-06-20 |
2023-08-12 |
Not clear |
| Sage J B Dunham, Paul D Hooker, Robyn M Hyd. Identification, extraction and quantification of the synthetic cannabinoid JWH-018 from commercially available herbal marijuana alternatives. Forensic science international. vol 223. issue 1-3. 2013-06-20. PMID:23092847. |
in this work, methods for the rapid identification, extraction, and quantification of the synthetic cannabinoid, jwh-018, from commercially available "spice" (a herbal marijuana alternative) are presented. |
2013-06-20 |
2023-08-12 |
Not clear |
| Antonia Manduca, Patrizia Campolongo, Viviana Trezz. Cannabinoid modulation of mother-infant interaction: is it just about milk? Reviews in the neurosciences. vol 23. issue 5-6. 2013-06-18. PMID:23104854. |
indeed, since cannabis sativa preparations are widely used by young people, including pregnant and lactating women, it is important to understand whether developmental exposure to cannabinoids interferes with mother-infant bond formation, potentially leading to neurodevelopmental alterations and increased vulnerability to psychopathology later in life. |
2013-06-18 |
2023-08-12 |
Not clear |
| Michael C Lee, Markus Ploner, Katja Wiech, Ulrike Bingel, Vishvarani Wanigasekera, Jonathan Brooks, David K Menon, Irene Trace. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain. vol 154. issue 1. 2013-06-18. PMID:23273106. |
nonetheless, the frontal-limbic distribution of cannabinoid receptors in the brain suggests that cannabis may target preferentially the affective qualities of pain. |
2013-06-18 |
2023-08-12 |
human |
| Maheswari Rajasekaran, Lisa K Brents, Lirit N Franks, Jeffery H Moran, Paul L Prathe. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicology and applied pharmacology. vol 269. issue 2. 2013-06-18. PMID:23537664. |
recent reports indicate that monohydroxylated metabolites of jwh-018 and jwh-073 retain high affinity and activity at cannabinoid type-1 receptors (cb1rs), potentially contributing to the enhanced toxicity of k2 compared to marijuana. |
2013-06-18 |
2023-08-12 |
human |
| Michael G Serpell, William Notcutt, Christine Colli. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. Journal of neurology. vol 260. issue 1. 2013-06-14. PMID:22878432. |
sativex is an endocannabinoid system modulator principally containing Δ(9)-tetrahydrocannabinol (thc) and cannabidiol (cbd). |
2013-06-14 |
2023-08-12 |
Not clear |
| John C Ashto. The atypical cannabinoid O-1602: targets, actions, and the central nervous system. Central nervous system agents in medicinal chemistry. vol 12. issue 3. 2013-06-13. PMID:22831390. |
o-1602 is a cannabidiol analogue that does not bind with high affinity to either the cannabinoid cb1 receptor or cb2 receptor. |
2013-06-13 |
2023-08-12 |
Not clear |
| Raphael Mechoulam, Linda A Parke. The endocannabinoid system and the brain. Annual review of psychology. vol 64. 2013-06-10. PMID:22804774. |
the psychoactive constituent in cannabis, Δ(9)-tetrahydrocannabinol (thc), was isolated in the mid-1960s, but the cannabinoid receptors, cb1 and cb2, and the major endogenous cannabinoids (anandamide and 2-arachidonoyl glycerol) were identified only 20 to 25 years later. |
2013-06-10 |
2023-08-12 |
Not clear |
| Delphine Psychoyos, K Yaragudri Vino. Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization. Drug testing and analysis. vol 5. issue 1. 2013-06-03. PMID:22887867. |
the relevance of these findings and potential adverse developmental consequences of in utero exposure to 'high potency' marijuana, spice branded products and/or cannabinoid research chemicals during this period is discussed. |
2013-06-03 |
2023-08-12 |
Not clear |
| Delphine Psychoyos, K Yaragudri Vino. Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization. Drug testing and analysis. vol 5. issue 1. 2013-06-03. PMID:22887867. |
finally, we address the implication of these findings in terms of the potential dangers of synthetic cannabinoid use during pregnancy, and the ongoing debate over legalization of marijuana. |
2013-06-03 |
2023-08-12 |
Not clear |
| Liana Fattor. Considering gender in cannabinoid research: a step towards personalized treatment of marijuana addicts. Drug testing and analysis. vol 5. issue 1. 2013-06-03. PMID:22887940. |
considering gender in cannabinoid research: a step towards personalized treatment of marijuana addicts. |
2013-06-03 |
2023-08-12 |
Not clear |
| Serena Deian. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug testing and analysis. vol 5. issue 1. 2013-06-03. PMID:23109356. |
recently, great attention has been directed to the medical properties of phytocannabinoids present in the cannabis plant alongside the main constituent Δ⁹-tetrahydrocannabinol (thc); these include cannabinoids such as cannabidiol (cbd), cannabigerol (cbg), and tetrahydrocannabivarin (thcv). |
2013-06-03 |
2023-08-12 |
Not clear |
| Rodrigo Ferretjans, Fabrício A Moreira, Antônio L Teixeira, João V Salgad. The endocannabinoid system and its role in schizophrenia: a systematic review of the literature. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 34 Suppl 2. 2013-05-17. PMID:23429846. |
this paper aims to review evidence supporting the involvement of the endocannabinoid system (ecs), a neurotransmitter group that is the target of cannabis sativa compounds, in this disorder. |
2013-05-17 |
2023-08-12 |
Not clear |
| Mateus M Bergamaschi, Erin L Karschner, Robert S Goodwin, Karl B Scheidweiler, Jussi Hirvonen, Regina H C Queiroz, Marilyn A Huesti. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clinical chemistry. vol 59. issue 3. 2013-05-14. PMID:23449702. |
impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. |
2013-05-14 |
2023-08-12 |
Not clear |
| A J Hill, M S Mercier, T D M Hill, S E Glyn, N A Jones, Y Yamasaki, T Futamura, M Duncan, C G Stott, G J Stephens, C M Williams, B J Whalle. Cannabidivarin is anticonvulsant in mouse and rat. British journal of pharmacology. vol 167. issue 8. 2013-05-06. PMID:22970845. |
phytocannabinoids in cannabis sativa have diverse pharmacological targets extending beyond cannabinoid receptors and several exert notable anticonvulsant effects. |
2013-05-06 |
2023-08-12 |
mouse |
| Jason M Wiebelhaus, Justin L Poklis, Alphonse Poklis, Robert E Vann, Aron H Lichtman, Laura E Wis. Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice. Drug and alcohol dependence. vol 126. issue 3. 2013-05-03. PMID:22776442. |
use of synthetic "marijuana" has increased in recent years, produced adverse effects and prompted the temporary dea ban of five specific cannabinoid analogs, including jwh-018. |
2013-05-03 |
2023-08-12 |
mouse |
| Concetta Catalano, Sidy Seck, Giuseppe Eni. Severe hyponatraemia during sepsis and marijuana addiction. BMJ case reports. vol 2011. 2013-04-29. PMID:22700344. |
the association between severe recurrent hyponatraemia during sepsis and marijuana addiction might not be casual, since experimental data show that vasopressin release induced by sepsis is modulated by the endocannabinoid system. |
2013-04-29 |
2023-08-12 |
Not clear |